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Key facts
Since their discovery in 1993, miRNAs have emerged as 
a new class of small RNAs that control intracellular gene 
expression networks at a post-transcriptional level. In the 
liver, miRNAs play fundamental roles in the regulation of 
physiological and pathological processes.
Conclusion
Despite their obvious potential as biomarkers, 
there are striking inter-study variances of miRNA-
regulation patterns in patients with hepatic diseases. 
As key prerequisites for a future clinical use- well-
standardized protocols have to be implemented for the 
analysis of miRNAs from patients’ serum. 
Open access under CC BY-NC-ND license.
Table 1. Selected studies on miRNA-serum alterations in human liver diseases.
miRNA biomarker Etiology Normalization Message [Ref.]
Up: miR-25, -92a, let7f, miR-375 HBV
(n ≈ 150)
None miR-375 is HBV specific and 
predicts HCC
Li et al., Cancer Res. 2010 Dec 1;70(23):9798-807
Up: miR-122 HBV (n = 83) U6 RNA Increase of miR-122 in HBV Zhang et al., Clin Chem. 2010 Dec;56(12):1830-8
Up: miR-122 HCV (n = 68) None miR-122 reflects liver damage Bihrer et al., Am J Gastroenterol. 2011 
Sep;106(9):1663-9
Up: miR-122, -34 NAFLD; HCV (n ≈ 35) Spike-in RNA miR-122 reflects liver damage 
and fibrosis
Cermelli et al., PLoS One. 2011;6(8): e23937
Up: miR-885-5p HBV, HCC
(n ≈ 100)
U6 RNA Increase in HCC Gui et al., Clin Sci (Lond). 2011 Mar;120(5):183-93
Up: miR-122, -222, -223
Down: miR-21
CHB, HCC (n = 118) miR-16 Deregulation in HCC Qi et al., PLoS One. 2011;6(12):e28486
Down: miR-29a 
Up: miR-133a
HCV, EtOH (n = 69) Spike-in RNA miR-29a reflects progression Roderburg et al., Hepatology. 2011 Jan;53(1):209-
18., J Hepatol. 2013 Apr;58(4):736-42
Up: miR-122, -192 Acetaminophen (n = 53) U6 RNA Increase reflects liver damage Starkey Lewis et al., Hepatology. 2011 
Nov;54(5):1767-76
Up: miR-21, -122, -223 HBV, HCC (n ≈ 150) miR-181 miRNAs are increased
increased in HBV, HCC
Xu et al., Mol Carcinog. 2011 Feb;50(2):136-42
Up: miR-21 -192, -801
Down: miR-26a, -27a, -122, -223
HBV, HCC (n ≈ 800) miR-1228 Differentiation between healthy, 
HBV and HCC
Zhou et al., J Clin Oncol. 2011 Dec 20;29(36):4781-8
Up: miR-122, -148a, -192 Liver transplant (n =107) Spike-in RNA miRNAs reflects transplantate 
rejection
Farid et al., Liver Transpl. 2012 Mar;18(3):290-7
Up: miR-571 
Down: miR-652
HCV, EtOH (n = 68) Spike-in RNA miR-29a reflects progression Roderburg et al., PLoS One. 2012;7(3):e32999
Up: miR-21 HBV, HCV, HCC 
(n = 166)
miR-16 miR-21 indicates HCC Tomimaru et al., J Hepatol. 2012 Jan;56(1):167-75
Up: miR-106b 
Down: miR181b
HBV (n = 62) miR-16 miRNAs reflects HBV infection Chen et al., PLoS One. 2013 Jun 21;8(6):e66577
Down: miR-197-3p, -505-3p HBV/HCV, PBC (n = 20) None Differentiation healthy, HBV/ 
HCV and PBC
Ninomiya et al., PLoS One. 2013 Jun 12;8(6):e66086
Up: miR-20a, -92a HCV (n = 58) Spike-in RNA miRNAs for early detection of 
HCV
Shrivastava et al., Hepatology. 2013 Sep;58(3):863-
71
Up: miR-122 HCV (n = 164) Spike-in RNA miR-122 reflects inflamm. and 
damage
Trebicka et al., J Hepatol. 2013 Feb;58(2):234-9
Up/down: 16 miRNA panel HBV in children (n = 60) None Panel of miRNAs reflects HBV 
in children
Winther et al., PLoS One. 2013 Nov 11;8(11):e80384
Up: miR-125-5p 
Down: miR-223-3p
HBV, HCC (n = 66) Spike-in RNA miRNAs reflect HCC and CLD- Giray et al., Mol Biol Rep. 2014 Mar 5
Up: miR-122 HCV (n = 25) U6 RNA miR-122 reflects HCV infection Kumar et al., Dis Markers. 2014;2014:435476Background
Since their discovery in 1993, miRNAs have emerged as a new class 
of small RNAs that control intracellular gene expression networks at a 
posttranscriptional level, thereby regulating biological processes like 
inflammation, fibrogenesis or carcinogenesis. miRNAs can also be 
detected and quantified in the blood, where they are found in nucleated 
and non-nucleated blood cells as well as in plasma and serum [1–4]. 
Circulating miRNAs are extraordinarily stable towards conditions that 
usually would degrade most RNAs. Recent studies have reported that 
plasma miRNAs exist in at least two different “protected” conditions: 
they can either be associated with RNA-binding proteins and 
lipoprotein complexes or they can be packaged into microparticles 
(exosomes, microvesicles and apoptotic bodies, reviewed in [4,5]).
  The exact distribution and function of miRNAs in these respective 
compartments has been controversially debated: a recent study 
suggested that the majority of miRNAs in serum or plasma are 
concentrated in exosomes [6], while, in contrast, other groups provided 
evidence that up to 90% of circulating miRNAs are associated with 
proteins [7]. By performing mass spectrometry, Wang et al. identified a 
panel of twelve binding partners for miRNAs, such as nucleophosmin 
1 and nucleolin, which have both been implicated in the nuclear export 
from ribosomes [8]. In contrast, the group of Arroyo provided evidence 
that most circulating miRNAs are associated with only one protein, 
namely Ago2, which is involved in miRNA mediated RNA silencing 
(reviewed in [4,5]).
  Different miRNAs were suggested to be enriched in specific 
extracellular compartments. However, these seem to vary between 
specific pathological conditions: In alcoholic liver disease and 
inflammation, increases in circulating miR-122 and miR-155 were 
restricted to the exosome-rich fraction, while in contrast, these miRNAs 
were predominantly increased in the protein-rich fractions during drug 
induced liver injury, suggesting that the shift of miRNAs from the protein-
bound to the exosomal compartment (and vice versa) might represent a 
cellular adaptation mechanism towards different disease conditions [9]. 
In line with this hypothesis, it was shown that exosomal miRNA profiles 
and concentrations do not necessarily reflect miRNA expression 
profiles found in donor cells, highlighting that miRNAs might actively be 
retained in cells or released by exosomes. Some studies even provided 
evidence that these exosomes can donate their miRNAs to recipient 
cells and thereby influence their gene expression [5,10], which would 
represent a novel mechanism of intercellular communication.Journal of Hepatology 2014 vol. 61 |  1434–1437 1435
Fig. 1. Cellular release of miRNAs during chronic hepatic diseases. After transcription from DNA and cleavage by the RNase III enzyme Drosha, so called pre-miRNAs are transported 
into the cytoplasm where they can be further cleaved into 19- to 23-nucleotide mature miRNA duplexes and loaded into the RNA-induced silencing complex (RISC) (to prevent translation 
of the mRNA into proteins). In the cytoplasm, pre-miRNAs as well as mature miRNAs may be incorporated into microparticles such as exosomes, apoptotic bodies or microvesicles and 
can be released from cells. Besides being included into vesicular structures, miRNAs are also present in a microparticle free compartment. These miRNAs are associated with high density 
lipoproteins or RNA-binding proteins (indicated as orange sphere, for details see text). Presently, it is only poorly understood how these miRNA-protein complexes are released from cells. 
In the course of hepatic diseases, miRNAs may be released passively (e.g., cell death), or actively, through secretion in vesicular structures or associated to proteins through interaction 
with specific membrane channels or proteins.
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Hepatology Snapshot   Considering these novel findings, miRNAs in body fluids have been 
investigated in a wide variety of patient samples and animal models 
and found considerable attention as biomarkers for disease conditions 
such as inflammation, fibrosis and cancer. Specifically in the field of 
hepatology, easily accessible serum based miRNAs might provide 
a novel tool in diagnosis and monitoring of liver diseases and might 
represent an alternative to invasive diagnostic procedures.
Functions of miRNAs in liver diseases
In the liver, miRNAs play fundamental functional roles in the 
regulation of physiological and pathological processes [11]. As such, 
miR-122 is the most abundant miRNAs in the liver, accounting for 
up to 72% of all hepatic miRNAs [12]. On a functional level, it was 
demonstrated that miR-122 is essential for liver homeostasis and its 
loss promotes steatosis, inflammation, fibrosis and liver cancer by 
regulating hepatic networks of genes involved in cell cycle regulation, 
lipid metabolism, inflammation and oncogenesis [12–14]. In humans, 
miR-122 expression was associated with hepatocarcinogenesis and 
miR-122 loss was associated with a poor prognosis of patients with 
hepatocellular carcinoma (HCC), while miR-122 overexpression 
sensitized HCC cells to chemotherapy and was associated with 
longer survival times [12]. Moreover, the stability of hepatitis C virus 
(HCV) is dependent on a functional interaction between the HCV 
genome and miR-122. By blocking this interaction with a specific 
antisense oligonucleotide, it was possible to inhibit viral replication 
in HCV patients [15], thus demonstrating the potential of miRNAs as 
therapeutic targets in liver disease. Besides miR-122, members of the 
miR-29 and miR-199 families have also been shown to be involved in 
several regulatory steps along the cascade leading from inflammation 
to fibrosis and HCC [16,17].
 
Alterations of circulating miRNAs in liver injury, inflammation and 
fibrosis
Based on their aberrant expression patterns in liver disease, levels 
of circulating microRNAs were analysed in the context of liver 
inflammation, fibrosis and cancer (Summarized in Table 1). Pilot 
studies in mice showed that miR-122 serum levels were elevated 
upon acetaminophen induced acute liver injury and were earlier 
markers of hepatocellular destruction than e.g., serum transaminases 
in this setting. In patients with chronic liver disease and liver fibrosis, 
array-based studies identified a whole panel of miRNAs, including 
miR-29a, miR-197-3p, miR-505-3p, miR-652, miR-20a, miR-21, 
miR-34a, miR-122, miR-133a, miR-223, miR-571, let7 and others that 
were deregulated in the serum compared to healthy controls, several 
of which also correlated with the degree of liver fibrosis. Of note, in 
most instances the functional link between the regulation of miRNA 
serum-levels and their roles in the specific cell compartments involved 
in fibrogenesis have remained unclear. In line, lower serum levels of 
miR-29 correlated with a downregulation in human hepatic stellate cells 
in liver cirrhosis, while alterations in serum levels of miR-652 reflected 
a concordant downregulation of this miRNA in circulating monocytes of 
cirrhosis patients. Moreover, elevated miR-122 serum levels correlate 
with hepatic cell death and necroinflammatory activity in patients 
with HCV infection but not with fibrosis stage or liver function. Finally, 
several reports suggested that alterations in serum levels of specific 
circulating miRNAs might allow a differential diagnosis between the 
different aetiologies of chronic liver disease [18].
Alterations of circulating miRNAs in hepatocellular carcinoma
Alterations in miRNA serum levels have been linked with various 
cancers, including HCC. Several miRNAs were suggested to be 
potential diagnostic and prognostic markers. However, most studies 
were limited by a small sample size, heterogeneous patients’ 
collectives or a small number of miRNAs explored. Moreover, the value 
of the miRNA signatures was often not prospectively evaluated and 
no external validation of the diagnostic accuracy of the deregulated 
miRNAs was conducted. Zhou and co-workers identified a panel of 
deregulated miRNAs with diagnostic potential featuring miR-21, miR-
122, miR-192, miR-223, miR-26a, miR-27a, and miR-801 in the serum Journal of Hepatology 2014 v1436 a large and well-defined cohort of HCC patients (Table 1). While the 
agnostic accuracy of single markers was insufficient, the whole panel 
d a much better diagnostic performance to differentiate patients 
ith HCC from control groups (AUROC 0.88). Another study in a large 
hort of patients with HBV- or HCV-associated HCCs revealed that 
e presence of HCC was associated with simultaneous elevation of 
iR-25, let-7f, and miR-375 in the serum and that miR-375 elevations 
e specifically linked with HBV-related hepatocarcinogenesis. These 
d other miRNAs might therefore be useful to monitor the cascade 
m liver injury to HCC.
scussion and outlook
espite their obvious potential as biomarkers, there are striking inter-
udy variances of miRNA-regulation patterns in patients with hepatic 
seases. Although miRNAs are very stable molecules in serum or 
asma, it is likely that a lack in standardization of sample collection, 
ta normalization and analysis might have biased many studies. 
us, for better comparability and reproducibility- as key prerequisites 
r a future clinical use- well-standardized protocols have to be 
plemented for the analysis of miRNAs from patients’ serum. If these 
rrent limitations can be overcome, the whole new cosmos of more 
an 1600 miRNAs might offer highly attractive options to establish 
w biomarkers in clinical hepatology.
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